回复：华金·马特奥、卡里姆·菲扎齐、西尔克·吉列森等人。《非转移性去势抵抗性前列腺癌的管理》。《欧洲泌尿外科杂志》2019年；75卷：285 - 93页。 - Suppr

Suppr

超能文献

Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.

作者信息

Rocco Bernardo, Sighinolfi Maria Chiara

机构信息

Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

出版信息

Eur Urol. 2020 Mar;77(3):e69. doi: 10.1016/j.eururo.2019.05.030. Epub 2019 May 29.

DOI:10.1016/j.eururo.2019.05.030

PMID:31151677

Abstract

摘要

相似文献

Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.回复：华金·马特奥、卡里姆·菲扎齐、西尔克·吉列森等人。《非转移性去势抵抗性前列腺癌的管理》。《欧洲泌尿外科杂志》2019年；75卷：285 - 93页。

Eur Urol. 2020 Mar;77(3):e69. doi: 10.1016/j.eururo.2019.05.030. Epub 2019 May 29.

Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.回复：华金·马特奥、卡里姆·菲扎齐、西尔克·吉列森等人。《非转移性去势抵抗性前列腺癌的管理》。《欧洲泌尿外科杂志》2019年；75卷：285 - 93页。

Eur Urol. 2020 Mar;77(3):e67-e68. doi: 10.1016/j.eururo.2019.06.026. Epub 2019 Jul 9.

Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485.

Eur Urol Oncol. 2020 Dec;3(6):806. doi: 10.1016/j.euo.2020.10.004. Epub 2020 Oct 22.

Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.回复：卡里姆·菲扎齐、查尔斯·G·德雷克、托马什·M·比尔等人。多西他赛后转移性去势抵抗性前列腺癌放疗后伊匹木单抗与安慰剂对比的III期试验最终分析确定了长期存活者过多。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.07.032：解读伊匹木单抗对多西他赛后转移性去势抵抗性前列腺癌患者放疗后的疗效

Eur Urol. 2021 Jan;79(1):e10-e11. doi: 10.1016/j.eururo.2020.09.049. Epub 2020 Oct 24.

Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.对伊桑·B·卢德米尔、扎卡里·R·麦考和李-珍·魏致编辑信的回复：关于卡里姆·菲扎齐、查尔斯·G·德雷克、托马什·M·比尔等人的研究。多西他赛后转移性去势抵抗性前列腺癌放疗后伊匹木单抗与安慰剂对比的III期试验最终分析确定了长期存活者过多。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.07.032。解读放疗后伊匹木单抗对多西他赛后转移性去势抵抗性前列腺癌患者的疗效。

Eur Urol. 2021 Jan;79(1):e12-e13. doi: 10.1016/j.eururo.2020.10.012. Epub 2020 Oct 26.

Re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035: Corticosteroid-associated Adverse Events in Elderly Patients.回复：卡里姆·菲扎齐、金·N·奇、约翰·S·德博诺等。长期给转移性去势抵抗性前列腺癌患者服用醋酸阿比特龙时联合低剂量泼尼松的情况下，皮质类固醇相关不良事件的发生率较低。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.02.035：老年患者的皮质类固醇相关不良事件

Eur Urol. 2016 Aug;70(2):e41. doi: 10.1016/j.eururo.2016.05.004. Epub 2016 May 12.

Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.回复：西尔克·吉列森、格哈特·阿塔尔德、托马什·M·比尔等。晚期前列腺癌患者的管理：2017年晚期前列腺癌共识会议（APCCC）报告。《欧洲泌尿外科杂志》2018年；73卷：178 - 211页。

Eur Urol. 2018 Feb;73(2):e31. doi: 10.1016/j.eururo.2017.08.010. Epub 2017 Aug 30.

Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012.回复：西尔克·吉列森、格哈特·阿塔德、托马什·M·比尔等人。晚期前列腺癌患者的管理：2019年晚期前列腺癌共识会议报告。《欧洲泌尿外科杂志》。2020年；77：508 - 547 https://doi.org/10.1016/j.eururo.2020.01.012

Eur Urol. 2020 Nov;78(5):e201-e202. doi: 10.1016/j.eururo.2020.03.012. Epub 2020 Mar 25.

Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.对吉安多梅尼科·罗维耶洛、阿尔贝托·博蒂尼和达尼埃莱·热纳利致编辑的信的回复，信的主题为：卡里姆·菲扎齐、金恩智、约翰·S·德博诺等人。长期给转移性去势抵抗性前列腺癌患者服用低剂量泼尼松龙联合醋酸阿比特龙时，皮质类固醇相关不良事件的发生率较低。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2016.02.035。老年患者中的皮质类固醇相关不良事件。

Eur Urol. 2016 Aug;70(2):e42. doi: 10.1016/j.eururo.2016.05.005. Epub 2016 May 18.

Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018;73:178-211.对芬恩·E·冯·艾本、艾琳·维尔戈利尼和詹多梅尼科·罗维耶洛致编辑的信的回复，信的主题为：西尔克·吉列森、格哈特·阿塔德、托马什·M·比尔等人。晚期前列腺癌患者的管理：2017年晚期前列腺癌共识会议（APCCC）报告。《欧洲泌尿外科杂志》2018年；73卷：178 - 211页。

Eur Urol. 2018 Feb;73(2):e32-e33. doi: 10.1016/j.eururo.2017.08.014. Epub 2017 Aug 30.

引用本文的文献

HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER.如何在晚期前列腺癌中最优地排列可用的治疗线。

Acta Clin Croat. 2022 Oct;61(Suppl 3):32-44. doi: 10.20471/acc.2022.61.s3.5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验